Cargando…

Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study

BACKGROUND: Invasive fungal diseases (IFD) remain a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) and are associated with high mortality rates in patients receiving alloHSCT. Antifungal prophylaxis is increasingly being used in the management of IFDs in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michallet, Mauricette, Cheikh, Jean El, Herbrecht, Raoul, Yakoub-Agha, Ibrahim, Caillot, Denis, Gangneux, Jean-Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994341/ https://www.ncbi.nlm.nih.gov/pubmed/35397492 http://dx.doi.org/10.1186/s12879-022-07216-6

Ejemplares similares

Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study
por: Gangneux, Jean-Pierre, et al.
Publicado: (2018)

Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study
por: Gangneux, Jean-Pierre, et al.
Publicado: (2020)

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Beauvais, D., et al.
Publicado: (2022)

Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience
por: Rahal, Ilhem, et al.
Publicado: (2018)

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT
por: Poiré, Xavier, et al.
Publicado: (2020)

Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents
por: Miller, Matthew A, et al.
Publicado: (2020)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders
por: Mahmoud, Hossam K., et al.
Publicado: (2015)

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
por: Zahid, Mohammad Faizan, et al.
Publicado: (2014)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
por: Lindsay, Julian, et al.
Publicado: (2021)

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
por: Greinix, Hildegard T., et al.
Publicado: (2021)

Management of psychiatric complications in unrelated donor before unrelated peripheral hematopoietic stem cell collections
por: Hequet, Olivier, et al.
Publicado: (2016)

Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation
por: Vantyghem, Marie-Christine, et al.
Publicado: (2014)

Short- and long-term outcomes in onco-hematological patients admitted to the intensive care unit with classic factors of poor prognosis
por: Faucher, Etienne, et al.
Publicado: (2016)

Rapid cardiovascular aging following allogeneic hematopoietic cell transplantation for hematological malignancy
por: Dillon, Hayley T., et al.
Publicado: (2022)

Antifungal management in ICU: careful follow-up of voriconazole prescription needed!
por: Reizine, Florian, et al.
Publicado: (2023)

Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages, and Potential Strategies
por: Pan, Hua, et al.
Publicado: (2016)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
por: Penack, Olaf, et al.
Publicado: (2021)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies
por: Na, Il‐Kang, et al.
Publicado: (2019)

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience
por: Diarra, Ava, et al.
Publicado: (2022)

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
por: Gahrton, Gösta, et al.
Publicado: (2020)

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Antar, Ahmad I., et al.
Publicado: (2020)

Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)
por: Pochon, Cécile, et al.
Publicado: (2021)

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia
por: Hodroj, Mohammad Hassan, et al.
Publicado: (2023)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups
por: Robin, Marie, et al.
Publicado: (2021)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies
por: Maurer, Stephen M., et al.
Publicado: (2022)

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2016)

Epidemiology of Invasive Fungal Diseases in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation Recipients Managed with an Antifungal Diagnostic Driven Approach
por: Bergamasco, Maria Daniela, et al.
Publicado: (2021)

1734. Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience in Colombia
por: Estacio, Mayra, et al.
Publicado: (2019)

591. Comparison of Fluconazole to Other Antifungal Agents in Allogeneic Hematopoietic Cell Transplant Recipients: A Meta-Analysis of Randomized Clinical Trials
por: Cheng, Ce, et al.
Publicado: (2021)

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
por: Perreault, Sarah, et al.
Publicado: (2023)

Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients
por: Busca, Alessandro, et al.
Publicado: (2016)

Use of antifungal drugs in hematology
por: Nucci, Marcio
Publicado: (2012)

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
por: Xu, Lanping, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_riadr8u6oc7qo80l2uq1hcfuaj